AzTrials
AzTrials

Acute Myocardial InfarctionNCT05862103

Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort

An observational study of Acute Myocardial Infarction and Adverse Event, run by Yu Bo at 18 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

AMI Survivors who participated in the project "Construction and key technology research of the whole myocardial protection system for acute myocardial infarction" (project number 2016YFC1301100) and completed the 1-year visit were followed up by telephone at 3 years (within the corresponding follow-up time window) and… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Myocardial Infarction, Adverse Event
What is being tested?
Treatment Strategies
How many people
14,517 participants
Where
18 sitesChina
Study dates
21 Dec 2022to 30 Aug 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: AMI survivors who participated in the project "Construction and key technology research on the whole myocardial protection system for acute myocardial infarction" and completed 1-year visit

Who may be able to join

  • AMI survivors who participated in the project "Construction and key technology research of the whole myocardial protection system for acute myocardial infarction" and completed the 1-year visit.
  • Telephone to obtain informed consent from the subjects/family members of the subjects.

Who cannot join

  • Not available

Trial locations and contacts

18 sites in 1 country.

18 sites in 1 country

China18 sites

  • Beijing An Zhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100029

  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, Beijing Municipality

  • Peking University First Hospital

    Beijing, Beijing Municipality

  • The Second Hospital of Jilin University

    Changchun, Jilin, 150056

  • Xinqiao Hospital Army Medical University

    Chongqing

  • The econd Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning

  • Daqing Oil Field Hospital

    Daqing, Heilongjiang

  • Guangdong general hospital

    Guangzhou, Guangdong

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330006

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, 210009

  • The first affiliated hospital of Guangxi medical university

    Nanning, Guangxi, 530021

  • General Hospital of Northern Theater Command of the Chinese People's Liberation Army

    Shenyang, Liaoning

  • Second hospital of hebei medical university

    Shijiazhuang, Hebei

  • The General Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality

  • Tianjin Chest Hospital

    Tianjin, Tianjin Municipality

  • First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang

  • Xijing Hospital of Air Force Military Medical University

    Xi’an, Shanxi

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan

Other trials in China

About this study

Official title: Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort - a Prospective, Multicenter Study

AMI Survivors who participated in the project "Construction and key technology research of the whole myocardial protection system for acute myocardial infarction" (project number 2016YFC1301100) and completed the 1-year visit were followed up by telephone at 3 years (within the corresponding follow-up time window) and 5 years after discharge to acquire the patients' medication, health status, and major adverse cardiovascular and cerebrovascular events, including death, heart failure, rehospitalization, re-myocardial infarction, revascularization, stroke, malignant arrhythmia, and bleeding events.

Being tested
Treatment Strategies
Keywords
Acute myocardial infarction, Major adverse cardiac and cerebrovascular event, Optimized treatment

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Treatment StrategiesOther

    AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion

Study groups in NCT05862103
Study groupRoleWhat they receive
optimized groupthe patients received at least one optimized treatment
Receives: Other: Treatment Strategies
un-optimized groupthe patients didn't receive optimized treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of MACCE

    the incidence of MACCE (death, heart failure, rehospitalization, re-myocardial infarction, re-myocardial revascularization, stroke, malignant arrhythmia, bleeding events, etc.) in AMI patients

    Measured: 5 years after discharge

Secondary outcomes (4)

  1. Differences of MACCE between the optimized group and the non-optimized group

    Differences of the MACCE between the optimized group and the non-optimized group

    Measured: 5 years after discharge

  2. Differences of the MACCE between OCT-guided group and the coronary angiography -guided group

    Differences of the MACCE between OCT-guided group and the coronary angiography -guided group

    Measured: 5 years after discharge

  3. Differences of MACCE between defer PCI group and direct PCI group

    Differences of MACCE between defer PCI group and direct PCI group

    Measured: 3 and 5 years after discharge

  4. Differences of the MACCE incidence between cardiac rehabilitation quality improvement group and non-cardiac rehabilitation group

    Differences of the MACCE incidence between cardiac rehabilitation quality improvement group and non-cardiac rehabilitation group

    Measured: 5 years after discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 May 2023
  2. Study start21 Dec 2022
  3. Primary completion30 Aug 2025
  4. Study completion30 Aug 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
14,517 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05862103
Sponsor's protocol ID
KY2022-266
Status last verified
Oct 2026
First submitted
8 May 2023
Last updated
16 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Myocardial Infarction and Adverse Event, run by Yu Bo at 18 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 18 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of MACCE (time frame: 5 years after discharge). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05862103.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in